Thierry Pieton
Summary
Thierry Pieton became Medtronic’s executive vice president and CFO on March 3, 2025, after serving as Renault Group’s CFO.
Biography
Pieton leads Medtronic’s global finance organization, including treasury, tax, controllership, financial planning and analysis, audit, investor relations, corporate strategy, business development, and portfolio management. He joined Medtronic after serving as Renault Group’s CFO from 2022 to 2025 and as a member of Renault’s leadership team. Earlier, Pieton held finance and administrative leadership roles at Renault and Nissan Motor Company, including senior vice president of administration and finance for Nissan Europe. He spent nearly 16 years in various finance roles at General Electric and GE Healthcare after beginning his career as an auditor at PricewaterhouseCoopers. Pieton graduated from EM Lyon Business School and completed executive programs at Northwestern University’s Kellogg School of Management and the University of Pennsylvania’s Wharton School.
Notable achievements
- At Renault, helped deliver the company’s highest-ever operating margins during his tenure as CFO.
- Helped improve Renault’s free cash flow and supported portfolio actions including acquisitions, divestitures, and development partnerships.
- Brought experience spanning finance, audit, healthcare, automotive, and other regulated manufacturing industries to Medtronic.
- Joined Medtronic as the company began emphasizing margin improvement, portfolio management, cost discipline, and earnings growth.
Problem areas / controversies
- Pieton is relatively new to Medtronic, so there is limited public evidence yet to assess his record at the company.
- He joined during a period when analysts had questioned Medtronic’s pace of margin expansion and profit growth.
- His prior record is closely associated with Renault’s restructuring and portfolio-management program, which may create execution and transition risks when applied to a large medical-device business.
- No major personal controversy or significant regulatory finding involving Pieton was identified in the public sources reviewed.